Inventor · disambiguated record
Matthew Lee
Also filed as: LEE MATTHEW · LEE MATTHEW R · LEE MATTHEW RANDOLPH
29 granted patents·6 pending applications·266 citations·filing 2002–2025
96Inventor score
Files withMIRATI THERAPEUTICS INC8AMGEN INC6CHDI FOUNDATION INC6CULLGEN SHANGHAI INC4Cervello Therapeutics LLC3
Top patents by PatentIndex Score
35 records- 0196US11091495B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Aug 17, 2021·4 cites·26 claims
- 0295US7652009B2Substituted heterocycles and methods of useAMGEN INC·Filed 2005·Granted Jan 26, 2010·33 cites·25 claims
- 0394US7514566B2Thiazole compounds and methods of useAMGEN INC·Filed 2007·Granted Apr 7, 2009·38 cites·48 claims
- 0493US7919504B2Thiadiazole modulators of PKBAMGEN INC·Filed 2008·Granted Apr 5, 2011·30 cites·16 claims
- 0592US11220509B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·2 cites·27 claims
- 0691US11267812B2KRAS G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Mar 8, 2022·11 cites·34 claims
- 0790US11992535B2Compounds and probes for imaging huntingtin proteinCHDI FOUNDATION INC·Filed 2020·Granted May 28, 2024·2 cites·39 claims
- 0890US9090593B2Bicyclic compounds as Pim inhibitorsWANG HUI-LING·Filed 2011·Granted Jul 28, 2015·26 cites·51 claims
- 0989US8088794B2Substituted amide derivatives and methods of useKIM TAE-SEONG·Filed 2010·Granted Jan 3, 2012·14 cites·14 claims
- 1087US7098336B2FXR NR1H4 nuclear receptor binding compoundsPHENEX PHARMACEUTICALS AG·Filed 2002·Granted Aug 29, 2006·18 cites·13 claims
- 1187US6974830B2NR1H4 nuclear receptor binding compoundsPHENIX PHARMACEUTICALS AG·Filed 2002·Granted Dec 13, 2005·32 cites·19 claims
- 1286US10266542B2EZH2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 23, 2019·6 cites·40 claims
- 1386US7687522B2Substituted pyridines and pyrimidines and their use in treatment of cancerAMGEN INC·Filed 2007·Granted Mar 30, 2010·8 cites·3 claims
- 1485US11806346B2HTT modulators for treating Huntington's diseaseCHDI FOUNDATION INC·Filed 2021·Granted Nov 7, 2023·1 cites·37 claims
- 1583US8685983B2Method of treating cancer with substituted amide derivativesKIM TAE-SEONG·Filed 2011·Granted Apr 1, 2014·7 cites·5 claims
- 1683US8017601B2Bis-aryl kinase inhibitors and methodAMGEN INC·Filed 2006·Granted Sep 13, 2011·7 cites·18 claims
- 1783US7915287B2Substituted heterocycles and methods of useAMGEN INC·Filed 2007·Granted Mar 29, 2011·4 cites·21 claims
- 1882US7034046B2NR1H4 nuclear receptor binding compoundsPHENEX PHARMACEUTICALS AG·Filed 2002·Granted Apr 25, 2006·19 cites·7 claims
- 1982US2025282787A1SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORSMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2081US11932633B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Mar 19, 2024·2 cites·41 claims
- 2181US11918662B2Heterocyclic compounds and imaging agents for imaging huntingtin proteinCHDI FOUNDATION INC·Filed 2021·Granted Mar 5, 2024·1 cites·8 claims
- 2280US12371435B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·20 claims
- 2371US8084479B2Thiazole compounds and methods of useZENG QINGPING·Filed 2009·Granted Dec 27, 2011·1 cites·20 claims
- 2469US12083108B2Compounds for targeting mutant huntingtin protein and uses thereofCHDI FOUNDATION INC·Filed 2022·Granted Sep 10, 2024·0 cites·17 claims
- 2569US2024066136A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2023·Application pending·0 cites
- 2668US11912719B2Substituted isoquinolines as rock kinase inhibitorsCervello Therapeutics LLC·Filed 2021·Granted Feb 27, 2024·0 cites·13 claims
- 2766US11485738B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·18 claims
- 2862US2023057177A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 2959US11248004B2Substituted isoquinolines as rock kinase inhibitorsCervello Therapeutics LLC·Filed 2020·Granted Feb 15, 2022·0 cites·17 claims
- 3058US11389438B2Compounds for targeting mutant huntingtin protein and uses thereofCHDI FOUNDATION INC·Filed 2020·Granted Jul 19, 2022·0 cites·9 claims
- 3156US2025235543A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 3254US12428413B2Rho kinase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2020·Granted Sep 30, 2025·0 cites·19 claims
- 3354US2024197694A1Modified proteins and protein bindersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 3440US10745381B2Substituted isoquinolines and phthalazines as rock kinase inhibitorsCervello Therapeutics LLC·Filed 2019·Granted Aug 18, 2020·0 cites·19 claims
- 3537US2007010562A1Nr1h4 nuclear receptor binding compoundsBAUER ULRIKE·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Lee files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →